Pharmacokinetic and Pharmacodynamic Comparison of Intravenous and Inhaled Caspofungin

Area of Science:

• Mycology
• Pharmacology
• Pulmonology

Background:

• Aspergillosis, a fungal lung infection caused by Aspergillus spp., poses a significant threat to immunocompromised individuals.
• Current intravenous antifungal treatments exhibit limited efficacy due to suboptimal drug distribution to the lungs.
• Understanding drug distribution and toxicity is crucial for improving aspergillosis treatment outcomes.

Purpose of the Study:

• To compare the pharmacokinetic profiles of intravenous (IV) and inhaled lung-targeted caspofungin in a rat model.
• To determine drug concentrations at the infection site and systemic distribution to assess potential toxicity.
• To elucidate the relationship between in vitro activity and in vivo efficacy of caspofungin.

Main Methods:

• Caspofungin was administered to rats via IV injection and nose-only inhalation at a single 2 mg/kg dose.
• Plasma and tissue samples were analyzed using high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS-MS).
• Pharmacokinetic parameters, including Cmax, AUC, and half-life, were compared between delivery methods.

Main Results:

• Inhaled caspofungin maintained lung drug levels above the minimum effective concentration for 168 hours, versus <24 hours for IV.
• The lung Cmax and AUC were 20 times higher with inhaled delivery compared to IV.
• Systemic distribution to the liver and kidney was 45% lower in the inhaled group than the IV group.

Conclusions:

• Lung-targeted inhaled caspofungin demonstrates superior pharmacokinetic and pharmacodynamic properties for treating pulmonary aspergillosis.
• This delivery method enhances therapeutic benefit by increasing lung drug concentration while minimizing systemic toxicity.
• Inhaled delivery facilitates a more convenient weekly dosing regimen compared to daily IV administration.